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Identity 
Other names: AADC 
HGNC (Hugo): DDC 
Location: 7p12.1 
Local order: Centromere to telomere. 
DNA/RNA 
Note 
The complete nucleotide structure of the human DDC 
gene has been determined from tissues of neural and 
non-neural origin (Sumi-Ichinose et al., 1992; Ichinose 
et al., 1992). The full DDC cDNA sequence has been 
cloned from human cells, such as pheochromocytoma 
(Ichinose et al., 1989), liver (Ichinose et al., 1992), 
hepatoma cells (Scherer et al., 1992), placenta (Siaterli 
et al., 2003), peripheral leukocytes (Kokkinou et al.,
2009b), as well as from several human cell lines, such 
as, U937 macrophage cells (Kokkinou et al., 2009a), 
SH-SY5Y, HTB-14 and HeLa cells (Chalatsa et al., 
2011). 
Description 
The human DDC gene exists as a single-copy in the 
haploid genome. It is composed of 15 exons and 14 
introns, spanning for more than 85 kbs (Sumi-Ichinose 
et al., 1992). The size of the exons was found to range 
from 20 to 406 bps (Sumi-Ichinose et al., 1992), 
whereas the size of the introns ranged from 927 to 
24077 bps (Sumi-Ichinose et al., 1992; Yu et al., 2006). 
The DDC gene is located in close proximity to the 
epidermal growth factor (EGF) gene (Craig et al., 
1992). 
Transcription 
Alternative splicing events are responsible for the 
production of two distinct DDC mRNAs, termed neural 
and non-neural, which differ in their 5' untranslated 
region (UTR). The neural-type transcript includes exon 
N1 (83 bps) that is located 17.8 kbs upstream of exon 
two. The non-neural type DDC mRNA bears exon L1 
(200 bps), which is located 4.2 kbs upstream to the 
location of exon N1. The second exon contains the 
translation start site and is located 22 kbs downstream 
from the non-neural (L1) exon (Ichinose et al., 1992). 
The transcription of the gene starts at position -111 
(Sumi-Ichinose et al., 1992). 
It has been reported that the two alternative DDC 
transcripts share identical coding regions and that t eir 
production is a result of alternative splicing and 
alternative promoter usage (Ichinose et al., 1992; Sumi-
Ichinose et al., 1995). Neural and non-neural promoters 
have been identified 5' to the flanking region of the 
respective exon 1 (Le Van Thai et al., 1993; Sumi-
Ichinose et al., 1995; Chatelin et al., 2001; Dugast-
Darzacq et al., 2004). The generation of the two 
alternative DDC mRNAs is not a mutually exclusive 
and tissue-specific event as previously thought (Siaterli 
et al., 2003; Vassilacopoulou et al., 2004; Kokkinou et 
al., 2009a; Kokkinou et al., 2009b; Chalatsa et al.,
2011).An alternative splicing event has been described 
within the coding region of DDC mRNA, leading to the 
formation of a shorter transcript lacking exon 3 
(O'Malley et al., 1995; Chang et al., 1996). 
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Table 1. Expression of DDC mRNA transcripts in human tissues, cells and cancer cell lines. 
 
It must be noted that the above authors did not specify 
the nature, neural or non-neural, of this shorter 
transcript. Recent evidence have revealed the neural 
nature of this alternative transcript in humans 
(Kokkinou et al., 2009a; Kokkinou et al., 2009b; 
Chalatsa et al., 2011). 
A novel DDC mRNA coding region splice-variant, 
resulting in the formation of a truncated DDC mRNA 
has been also identified. This human DDC mRNA (1.8 
kbs), termed as Alt-DDC, lacks exons 10-15 of the full-
length transcript, but includes an alternative exon 10 
(Vassilacopoulou et al., 2004). The Alt-DDC exon 10 
(358 bps) was found within intron 9 of the DDC gene. 
Although Alt-DDC mRNA was detected in human 
placenta, high expression levels of this alternative 
transcript were found in human kidney 
(Vassilacopoulou et al., 2004). 
The notion that transcription of the human DDC gene 
leads to the production of multiple mRNA isoforms, 
which are expressed in a non-mutually exclusive and
tissue-specific manner, underlines the complexity of 
the expression patterns of this gene (table 1). 
Pseudogene 
None has been identified yet. 
Protein 
Note 
Although, it was initially suggested that the DDC gene 
encoded for a single protein product (Sumi-Ichinose et 
al., 1992), evidence that demonstrated the expression of 
additional DDC protein isoforms in humans, argue 
against it (O'Malley et al., 1995; Chang et al., 1996; 
Vassilacopoulou et al., 2004). 
Description 
The DDC enzyme (EC 4.1.1.28) was initially purified 
and characterized from pig kidney (Christenson et al., 
1970) as well as from the insects Calliphora vicina 
(Fragoulis and Sekeris, 1975) and Ceratitis capitata 
(Mappouras and Fragoulis, 1988; Bossinakou and 
Fragoulis, 1996). DDC is a homodimer of 100-110 
kDa, with a subunit molecular mass of 50-55 kDa 
(Voltattorni et al., 1979; Mappouras et al., 1990; 
Bossinakou and Fragoulis, 1996). The full-length 
protein molecule consists of 480 amino acids (Ichinose 
et al., 1989). DDC is a pyridoxal-5-phosphate (PLP)-
dependent enzyme possessing a single binding-site for 
PLP per subunit (Voltattorni et al., 1982; Ichinose et 
al., 1989; Burkhard et al., 2001). 
Expression of the DDC gene, in humans, results in the 
production of additional protein isoforms (O'Malley t 
al., 1995; Chang et al., 1996; Vassilacopoulou et al., 
2004). O'Malley et al. (1995) identified of a new DDC 
protein isoform (O'Malley et al., 1995). The truncated 
DDC protein isoform (Mr; 50 kDa) consists of 442 
amino acid residues (DDC442). This isoform was found 
to be inactive towards the decarboxylation of both L-
Dopa to Dopamine and 5-Hydroxytryptophan (5-HTP) 
to serotonin (O'Malley et al., 1995). As mentioned 
above, the translation of Alt-DDC mRNA resulted in 
the synthesis of a truncated 338 amino acid long 
polypeptide, termed as Alt-DDC (Mr; 37 kDa). This 
isoform was identical to the full-length DDC protein up 
to amino acid residue 315. The remaining 23 amino 
acids of the C-terminal sequence are encoded by the 
alternative DDC exon 10 and are not incorporated in  
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Table 2. Human DDC identity. 
 
the full-length DDC protein sequence (Vassilacopoulou 
et al., 2004). 
Although previous data had suggested that DDC was a 
rather unregulated molecule, several findings have 
indicated that DDC activity can be modulated by many 
factors, such as D1, DA receptor antagonists (Rossetti 
et al., 1990), a2-adrenergic receptor antagonists 
(Rossetti et al., 1989), D1, D2 receptor antagonists 
(Zhu et al., 1992; Hadjiconstantinou et al., 1993), DA 
receptor agonists (Zhu et al., 1993), PK-A and PK-C 
mediated pathways (Young et al., 1993; Young et al., 
1994) and by endogenous inhibitors isolated from 
human serum (Vassiliou et al., 2005) and placenta 
(Vassiliou et al., 2009). 
Expression 
DDC has been detected throughout the length of the 
gastrointestinal tract (Eisenhofer et al., 1997) and i  
blood plasma (Boomsma et al., 1986). DDC is 
expressed in normal human kidney and placenta 
(Mappouras et al., 1990; Siaterli et al., 2003). DDC 
expression was observed in normal peripheral 
leukocytes and T-lymphocytes (Kokkinou et al., 
2009b). Furthermore, DDC is expressed in the human 
cancer cell lines U937 (Kokkinou et al., 2009a), SH-
SY5Y, HeLa and HTB-14 (Chalatsa et al., 2011). 
Interestingly, the expression of the alternative DDC 
isoform (Alt-DDC) was also demonstrated in peripheral 
leukocytes (Kokkinou et al., 2009b), U937 (Kokkinou 
et al., 2009a), SH-SY5Y and HeLa cell lines (Chalatsa 
et al., 2011). 
In the central nervous system, increased DDC 
enzymatic activity is detected in the hypothalamus, 
epiphysis, striatum, locus ceruleus, olfactory bulb and 
retina (Park et al., 1986). Elevated enzymatic DDC 
activity is also detected in peripheral organs such as 
liver, pancreas, kidney, lungs, spleen, stomach, salivary 
glands, as well as in the endothelial cells of blood 
vessels (Lovenberg et al., 1962; Rahman et al., 1981; 
Lindström and Sehlin, 1983). 
Localisation 
DDC was considered to be a cytosolic molecule 






Nevertheless, additional experimental findings have 
demonstrated that a population of enzymatically active  
DDC molecules is associated with the cellular 
membrane fraction in the mammalian CNS (Poulikakos 
et al., 2001). Membrane-associated, enzymatically 
active DDC subpopulations were detected in the highly 
hydrophobic fractions of normal human leukocytes and
U937 cancer cells (Kokkinou et al., 2009a; Kokkinou et 
al., 2009b). 
Function 
In terms of substrate specificity, the DDC molecule 
purified from insects demonstrated a remarkably high 
affinity towards the decarboxylation of L-Dopa to 
dopamine (Fragoulis and Sekeris, 1975; Mappouras 
and Fragoulis, 1988; Bossinakou and Fragoulis, 1996). 
However, work by Mappouras et al. (1990) in the 
normal human kidney has suggested that the enzyme is 
capable of also decarboxylating L-5-
Hydroxytryptophan to serotonin, although the 
decarboxylation activity towards L-5-
Hydroxytryptophan was found to be considerably lower 
than the one observed for L-Dopa (Mappouras et al., 
1990). Since DDC expression results in the production 
of multiple protein isoforms, it is conceivable that these 
different protein molecules could be responsible for the 
decarboxylation of other aromatic L-amino acids. 
Homology 
Comparison of the amino acid sequence of DDC from 
different species, suggested that the enzyme is an 
evolutionarily conserved molecule. The amino acid 
sequence around the coenzyme binding lysine is also 
evolutionarily conserved (Bossa et al., 1977; Ichinose 
et al., 1989). The conserved amino acids are residu 
267-317, which surround the PLP-binding site 
(Ichinose et al., 1989), as well as, the extended regions 
of amino acids 64-155 and 182-204, which according 
to Maras et al. (1991) are important for the enzyme's 
catalytic function (Maras et al., 1991). Table 2 shows 
the percentage of human DDC amino acid identity to 
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Mutations 
 
Table 3. The mutations of the DDC gene in the AADC disorder. 
Germinal 
Such mutations have not been identified so far. 
Somatic 
Aromatic L-amino acid decarboxylase (AADC) 
deficiency, a rare autosomaly-recessive inherited 
defect, is associated with mutations of the DDC gene. 
This disorder leads to profound modifications in the 
homeostasis of central and peripheral nervous system 
(Hyland et al., 1992). In their majority, such mutations 
are missense and are listed above (table 3). Other 
mutations of the human DDC gene that are related to 
AADC-deficiency are also included (Fiumara et al., 
2002; Chang et al., 2004; Pons et al., 2004; Tay et al., 




Neuroendocrine differentiation features have been 
identified in prostatic adenocarcinoma. Aggressiveness 
of the disease is increased as the cells reach the 
androgen-independent phase (Speights et al., 1997; 
Nelson et al., 2002). L-Dopa decarboxylase has been 
identified as a novel androgen receptor (AR) 
coactivator protein (Wafa et al., 2003). Recent evid nce 
have shown that the expression of DDC mRNA could 
serve as a potential novel biomarker in prostate cancer 
(Avgeris et al., 2008). Wafa et al. (2007) have indicated 
by immunohistochemistry that DDC was found to be a 
putative neuroendocrine marker for prostate cancer. In 
certain NE tumor cells of the prostate gland, DDC was 
found to be co-expressed with AR. DDC expression 
was increased after hormone-ablation therapy, as well 
as, in metastatic tumors that have progressed to the 
androgen-independent phenotypes (Wafa et al., 2007). 
Disease 
Increased DDC mRNA and/or elevated protein 
expression levels were detected in the LnCaP cell line 
following synthetic androgen treatment. DDC protein 
was found to be enzymatically active in the androgen-
treated LnCaP cells as compared to the untreated 
controls. In treated LnCaP cells, DDC was up-regulated 
during AR-activation, while DDC expression was 
down-regulated following AR-inhibition. These 
findings support a coactivator role for DDC in AR 
activation (Shao et al., 2007). DDC over-expression 
affects the gene expression profile of the androgen-
dependent prostate cancer cell line, LnCaP, as reveal d 
by microarray analysis (Margiotti et al., 2007). 
Prognosis 
Statistically significant elevated DDC mRNA levels 
were observed in prostate cancer tissue specimens 
when compared to benign hyperplasia human samples.  
Multivariate survival analysis indicated that the 
expression of the DDC gene could be used as an 
independent marker for the differential diagnosis 
between prostate cancer and benign hyperplasia 
patients, using tissue biopsies. DDC mRNA expression 
was also shown to be associated with advanced tumor 
stage and higher Gleason score. This finding suggested 
an unfavorable prognostic value for DDC expression in 




High L-Dopa decarboxylase activity has been detected 
in almost half of the original colorectal carcinomas 
examined, as well as, in the majority of cultured cell 
lines, established from human primary and metastatic 
tumors (Park et al., 1987). Other data have shown that 
most solid colorectal tumors exhibited DDC activity at 
lower levels when compared to the enzymatic DDC 
activity displayed by the NE tumors (Gazdar et al.,
1988). DDC mRNA expression was found to be 
elevated in well-differentiated (grade I) intestinal 
adenocarcinomas as compared to more aggressive 
tumors (Kontos et al., 2010). 
Prognosis 
Increased DDC mRNA levels were observed in grade I 
colorectal adenocarcinomas. Survival analysis reveal d 
a significantly lower risk of disease recurrence and 
longer overall survival for patients with DDC-positive  
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colorectal neoplasms. These results indicate that DDC 
mRNA expression might represent a possible future 
biomarker for the prognosis of colorectal cancer 
patients (Kontos et al., 2010). 
Gastric cancer 
Note 
Advanced gastric cancer is characterized by peritoneal 
dissemination, the most common disease relapse, which 
is caused by the dispersal of free gastric cancer cells
into the peritoneal cavity (Baba et al., 1989; Abe et al., 
1995). 
Disease 
It has been proposed that increased DDC mRNA 
expression could be an accurate tool for the detection 
of gastric cancer micrometastases in the peritoneal 
cavity. According to Sakakura et al. (2004), DDC 
expression levels were equivalent to the degree of 
dissemination potential of gastric cancer cells. 
Pheochromocytomas 
Note 
Pheochromocytomas are characterized by over-
production of catecholamines (Eisenhofer et al., 2001). 
Disease 
These non-innervated tumors originate, in most cases, 
from adrenal medullary cells which are capable for 
catecholamine biosynthesis (Yanase et al., 1986). 
Catecholamine release by these cells is not initiated by 
nerve impulses. Elevated DDC mRNA levels have been 
detected in pheochromocytoma tissues as compared to 
normal adrenal medullary cells. Isobe et al. (1998) 
suggested that high DDC expression could lead to the 
development or growth of pheochromocytomas (Isobe 
et al., 1998). 
Neuroblastomas 
Note 
In the neuroblastoma cell line, the SH-SY5Y cells, both 
neural full-length DDC mRNA and the neural mRNA 
isoform lacking exon 3, were detected (Chalatsa et l., 
2011). 
Disease 
Neuroblastomas, the most common extracranial solid 
neoplasms in children, originate from sympathetic 
neural crest cells and their characteristic is the 
production of catecholamines and their metabolites 
(Boomsma et al., 1989). Neuroblastomas are 
categorized as small round-cell tumors of the childhood 
(Gilbert et al., 1999). In the active untreated state, 
plasma L-Dopa values and/or DDC enzymatic activity 
levels have been found to be elevated. Interestingly, 
following chemotherapy treatment, DDC enzymatic 
activity levels fall within the physiological range. 
Elevated levels of plasma L-Dopa and especially DDC 
enzyme activity are observed during disease relapse 
(Boomsma et al., 1989).  
It is noted that conventional light microscopy cannot 
clearly differentiate between neuroblastoma and other 
small round-cell tumors of the childhood. Co-
expression of DDC and Tyrosine Hydroxylase (TH) 
has been used for the differential diagnosis of these 
types of tumors (Gilbert et al., 1999). 
Prognosis 
Elevated levels of plasma L-Dopa, in neuroblastoma 
patients, could provide an indication for residual t mor. 
These findings could be associated with dismal 
prognosis for neuroblastoma patients. Furthermore, a 
sharp increase in plasma DDC enzymatic activity could 
be related to disease reccurence (Boomsma et al., 
1989). DDC mRNA was detected in all bone marrow 
and peripheral blood samples obtained from 
neuroblastoma patients at relapse. Given these results, 
Bozzi et al. (2004) have suggested that DDC mRNA 
expression could represent a specific molecular marker 
for monitoring bone marrow and peripheral blood 
neuroblastoma metastases (Bozzi et al., 2004). 
Furthermore, DDC mRNA levels could be used as a 
sensitive indicator to predict minimal residual disea e 
as well as the outcome for patients (Träger et al., 2008). 
Lung carcinomas 
Note 
Elevated DDC enzymatic activity was observed in 
small-cell lung carcinoma (SCLC) as compared to 
normal lung epithelia (Nagatsu et al., 1985). The 
majority of non-SCLC (NSCLC) exhibited low levels 
or no DDC enzyme activity (Gazdar et al., 1981; 
Bepler et al., 1988). It is noted that in some NSCLC 
cases, high DDC activity values have been reported 
(Baylin et al., 1980), although in these lung lesion  the 
detection of DDC activity was restricted to large-cell 
carcinomas and adenocarcinomas, while squamous cell 
carcinomas did not exhibit any enzymatic activity 
(Gazdar et al., 1988). 
Disease 
DDC activity appears to be a valuable neuroendocrine 
marker for identifying SCLC tumor cells in culture 
(Baylin et al., 1980). DDC enzymatic activity is hig est 
during the exponential cellular growth phase and/or 
when the cells are during the transition from G2 to the 
M phase of the cell cycle (Francis et al., 1983). DDC 
activity has been also used as a useful biomarker for the 
distinction of SCLC from NSCLC. Furthermore, DDC 
activity has been used for the differentiation between 
the classical SCLC cell lines (SCLC-C), which express 
high DDC activity levels, from the variant subtype of 
the SCLC (SCLC-V), which does not express the 
enzyme (Carney et al., 1985; Gazdar et al., 1985). 
Prognosis 
The elevated DDC enzymatic activity, which is 
observed in patients harboring SCLC tumors, seems to 
be associated with disease differentiation grade. High 
DDC activity has been associated with better prognosis 
and patient's outcome (Bepler et al., 1987). 
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Medullary thyroid carcinoma 
Note 
The expression of L-Dopa decarboxylase has been 
detected in medullary carcinoma of the thyroid gland 
(Pearse, 1969; Atkins et al., 1973). 
Disease 
Medullary thyroid carcinoma (MTC) originates from 
the calcitonin (CT)-secreting thyroid C cells and is a 
unique malignancy of endocrine origin (Tashjian and 
Melvin, 1968). Malignancy progression could be 
monitored, in patients with the virulent phenotype of 
the disease, using the simultaneous increased levels of 
DDC and histaminase (Trump et al., 1979; Lippman et 
al., 1982). It has been proposed that increased DDC 
enzymatic activity might represent an early 
differentiation marker in the virulent form of this 
neoplasm (Berger et al., 1984). 
Neuroendocrine tumors (NETs): 
bronchial, liver and ileal carcinoids, 
gastric / pancreatic / pulmonary tumors 
Note 
DDC enzymatic activity constitutes an excellent 
cellular marker for identifying tumors of the 
neuroendocrine (NE) origin. The majority of NE 
tumors tested were found to express relatively high 
DDC enzymatic activity (Gazdar et al., 1988). DDC 
expression and/or activity have been reported in NETs, 
particularly in SCLC. For these reasons, DDC has been 
considered as a general endocrine marker (Gazdar et 
al., 1988; Jensen et al., 1990). 
Disease 
Strikingly higher DDC mRNA expression levels were 
revealed in all bronchial carcinoids and pulmonary 
NETs when compared to their normal corresponding 
types of tissues. Immunohistochemical data have 
confirmed DDC protein expression in all of these 
tumors. In the gastroenteropancreatic NETs examined, 
the detected DDC mRNA levels were comparable to 
those of normal gastric, ileal and pancreatic tissue . 
Almost half of the pancreatic and stomach NETs and 
all ileal carcinoids were found to be DDC 
immunoreactive (Uccella et al., 2006). Interestingly, 
hepatic carcinoid tumors demonstrated a 20-fold 
increase in DDC activity as compared with normal 
surrounding liver tissues (Gilbert et al., 1995). 
Hybrid/Mutated gene 
Not yet discovered. 
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